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1300Abstract: To understand how patient demographics and patient-reported disease characteristics
relate to successful management of postherpetic neuralgia (PHN), integrated data from phase 3 and
phase 4 studies of patients with PHN (n = 546) who received once-daily gastroretentive gabapentin
(G-GR, 1800 mg) were analyzed. There were widespread, networked, positive correlations among effi-
cacy endpoints—pain qualities on the visual analog scale (VAS) andBrief Pain Inventory (BPI),measures
of pain interference on the BPI, and Patient Global Impression of Change (PGIC)—most likely character-
izedbypositive feedback loops, inwhichpain interfereswithpatient functioning, andpoor functioning
enhances pain. VAS scores at baseline or at week 2 were the strongest predictors of being ‘‘much’’ or
‘‘very much’’ improved on the PGIC; BPI sleep interference scores were the strongest predictors of
percent changes in BPI pain qualities and in the average of BPI interference scores, whereas age, sex,
and racewere not important predictors. In addition toVAS, BPI sleep interference and PGIC assessments
appeared to be key co-strategic factors important for successful treatment outcomes, and should be
considered as co-primary end points in future clinical trials of PHN. This could improve detection of
true positive efficacy responses and guide successful transition to real-world clinical practice.
Perspective: This study describes complex relationships among measures of pain intensity, pain
interference with daily activities, and demographics of patients with PHN treated with G-GR. Such
comprehensive characterization provides important insight into how different variables contribute
to successful treatment, and may lead to better management of neuropathic pain.
ª 2015 The Authors. Published by Elsevier Inc. on behalf of the American Pain Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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.doi.org/10.1016/j.jpain.2015.08.011a painful skin rash with blisters.19,45 The symptoms of
herpes zoster typically resolve within 2 to 4 weeks, but
approximately 10 to 20% of patients develop
postherpetic neuralgia (PHN), a neuropathic pain
condition.11,28,31,44 PHN is commonly defined as pain
persisting for more than 3 months after the healing of
the herpes zoster rash, although it can persist for more
than a year.44 Recommended first-line treatment options
for PHN include gabapentinoids (various formulations of
gabapentin and pregabalin), tricyclic antidepressants,
and the topical lidocaine 5% patch.2,5,13 The
gastroretentive formulation of gabapentin (G-GR),
approved by the US Food and Drug Administration
(FDA) for treatment of PHN, uses a polymer-based tech-
nology to swell when the tablets come in contact with
gastric fluid, and is retained in the stomach for 8 to
Kantor et al The Journal of Pain 130110 hours,1,16 allowing for once-daily dosing and a
simple 2-week titration regime. In 2 phase 3 placebo-
controlled studies and in 1 phase 4 open-label study,
once-daily 1800 mg of G-GR provided significant pain
relief, significantly reduced pain interference with daily
activities, and demonstrated a good safety and tolera-
bility profile in patients with PHN, including in older
patients.12,25,37,43
Available treatments for PHN focus on shortening the
duration and severity of the pain. However, neuro-
pathic pain associated with PHN can be debilitating,
and it frequently interferes with patients’ physical and
social functioning.4 Therefore, in addition to pain relief,
improvement in various aspects of pain interference
with patients’ daily lives may provide quality patient
care and improve patients’ overall well-being. Several
instruments that measure the effect of treatment on
pain intensity and on other pain qualities, as well as
on how pain affects various aspects of patients’ lives,
have been developed and are commonly used in clinical
studies of pain therapies.7 Among these, the visual
analog scale (VAS) is among the most frequently used
instruments to measure pain intensity.14 The Brief Pain
Inventory (BPI) measures both the intensity of pain
(worst, least, average, and current pain) and the inter-
ference of pain in 7 aspects of patient’s functioning
(general activity, mood, walking ability, normal work,
relationships, sleep, and enjoyment of life).3 The Patient
or Clinical Global Impression of Change (P/CGIC) is
commonly used to assess overall efficacy and treatment
experience.22
Pain intensity is the most common primary outcome
variable assessed in studies of pain therapies, including
in PHN, whereas measures of patients’ quality of life
and how pain interferes with their functioning are sec-
ondary efficacy measures. Because pain frequently inter-
feres with daily activities, measures of pain intensity
would be expected to be positively associated with mea-
sures of pain interference with patient functioning.
Levels of pain intensity and its interference recorded at
baseline may influence the effectiveness of treatment.
Also, the complexity of pain and its interference with
functioning is largely dependent on subjective reporting
by patients, and patient demographics (ie, age, sex, or
race) may influence self-reporting. Moreover, age, sex,
and race have been reported to be differentially associ-
ated with the experience of pain,8,26,34 which may also
influence treatment outcomes.
A major risk factor for PHN is advanced age, with
approximately half of all PHN cases occurring in patients
older than 60 years, and female sex has been reported to
be an important risk factor among others.21,29,44,45 Also,
racemay influence susceptibility to herpes zoster, thus to
subsequent PHN6,40; and individual genetic factors may
prove important for specifically targeted treatment of
neuropathic pain.38 Therefore, studying relationships
among patient demographics, disease characteristics,
pain severity, and corresponding levels of pain interfer-
ence with daily activities can identify factors important
for multidimensional treatment of PHN in clinical
practice.Although there are a number of publications
describing risk factors for PHN as well as factors that
affect pain experience, comprehensive analyses on how
various baseline characteristics can influence PHN treat-
ment outcomes have not been performed. Therefore,
the goal of the current, secondary analysis of integrated
data from the phase 3 and 4 studies of G-GRwas to better
understand how patient characteristics and key patient-
reported outcome measures relate to patients’ overall
well-being after treatment with G-GR. Such comprehen-
sive analysis may identify factors important for multidi-
mensional responses to treatment that can potentially
inform the design and evaluation of treatment strategies
for better management of PHN.Methods
Patients
Data from patients treated with G-GR in 2 phase 3,
double-blind, randomized, placebo-controlled studies
(81-0045 and 81-0062) and 1 phase 4, open-label, sin-
gle-arm study (81-0067) were integrated before this
analysis. Patients treated with placebo in phase 3 studies
were not included in this analysis because this would
have resulted in uneven G-GR versus placebo patient
populations. Also, various exploratory analyses of inte-
grated data from phase 3 studies for differences be-
tween patients treated with G-GR and patients treated
with placebo were published previously.10,12,17,18,33
The main patient inclusion criteria for the phase 3
studies were age $18 years with neuropathic pain for
$3 months (81-0045) or $6 months (81-0062) after the
healing of herpes zoster skin rash; and an average daily
pain score of$4 based on an 11-point Likert scale (where
0 = no pain and 10 = worst possible pain), at the end of a
1-week pretreatment baseline period. Main exclusion
criteria included previous lack of response to treatment
with $1200 mg/day gabapentin or $300 mg/day prega-
balin; dose-limiting adverse events with gabapentin or
hypersensitivity to gabapentin; use of any concomitant
medication excluded by the inclusion criteria (including
capsaicin, opiates, topical lidocaine, anticonvulsants,
and serotonin and norepinephrine reuptake inhibitors);
and creatinine clearance (CrCl) <50 mL/min. For the
phase 4 study, patients were relatively unselected to
reflect the real-world population, and included patients
$18 years with active PHN, regardless of their baseline
pain scores. Exclusion criteria were limited to those in
the product label: pregnant women or nursing mothers,
patients with hypersensitivity to gabapentin, and pa-
tients who had an estimated Cr/Cl <30 mL/min or who
were on hemodialysis. There were no restrictions on
the use of prior medications in the phase 4 study, and
the use of concomitant neuropathic pain medication
was permitted.
Treatments
All 3 studies shared a similar G-GR treatment schedule.
Patientswere titrated to 1800mg/dayG-GR over 2weeks,
followed by 8 weeks (phase 3) or 6 weeks (phase 4) of
1302 The Journal of Pain Treatment of Postherpetic Neuralgiastable dosing with G-GR 1800 mg taken once daily with
the evening meal. Therefore, the end of the study in
the current analysis was defined asweek 10 for the phase
3 studies and week 8 for the phase 4 study. The 2-week
titration period used a set schedule: day 1, 300 mg; day
2, 600 mg; days 3‒6, 900 mg; days 7‒10, 1200 mg; days
11‒14, 1500 mg; day 15, 1800 mg. The schedule for 1-
week dose tapering was 2  600 mg for 3 days and
1  600 mg for the last 4 days.Efficacy Evaluations
Efficacy assessments common for phase 3 and 4
studies, and thus used in the current secondary analysis,
were the VAS for the assessment of pain intensity on the
100-mm scale, the BPI for the assessment of pain qualities
and pain interference on the 0‒10 Numerical Rating
Scale (NRS;where 0 = no pain interference and 10 =worst
possible pain/interference), and the Clinical/Patient
Global Impression of Change (C/PGIC) for the assessment
of overall improvement. On the BPI, changes in patients’
perceived pain (worst, least, average, and current pain)
and the degree to which their pain interfered with their
life and activities (general activity, mood, walking ability,
normal work, relationship, sleep, enjoyment of life, and
the average of 7 interference scores) were measured. On
the CGIC or PGIC, the proportion of patients categorized
as ‘‘very much improved,’’ ‘‘much improved,’’ ‘‘minimally
improved,’’ ‘‘no change,’’ ‘‘minimally worse,’’ ‘‘much
worse,’’ or ‘‘very much worse’’ was determined. VAS
and BPI were completed at baseline, at week 2 (end of
titration), and at the end of the study (week 10 for phase
3 and week 8 for phase 4). CGIC and PGIC were
completed at the end of the study.Statistical Methods
To remain compliant with clinical trials, patient
populations and statistical methods were largely
based on FDA-approved statistical plans of the individual
phase 3 and 4 studies.25,37,43 Patients who took $1
dose of G-GR, had a valid baseline measurement,
and completed $1 post-baseline efficacy assessment
(intent-to-treat [ITT] populations in the individual
studies) were included in the efficacy population.
Patients who completed each individual study (10 weeks
of treatment in phase 3 and 8 weeks of treatment in
phase 4) were included in the completer population.
Mean (standard error of the mean [SEM]) changes
from baseline to the end of the study in the VAS and
BPI scores, and the proportion of patients categorized
on the CGIC and PGIC at the end of the study were deter-
mined. Changes from baseline in the VAS and BPI inter-
ference scores were estimated with an analysis of
covariance model that included treatment, study cen-
ters, and the baseline value as covariates. Missing data
were imputed by the last observation carried forward
method. In agreement with the published literature
and the consensus summary statement produced by the
Initiative on Methods, Measurement, and Pain Assess-
ment in Clinical Trials,7,9,30 reductions of $30% from
baseline until the end of the study served asdeterminants of clinically important reductions in the
VAS or BPI scores (VAS or BPI responders). PGIC
responders were defined as patients who reported
feeling ‘‘much’’ or ‘‘very much’’ improved at the end of
G-GR treatment, whereas PGIC nonresponders were
defined as patients who did not (ie, patients in all
other PGIC categories).
To evaluate the degree of a linear relationship among
percent changes in efficacy variables, bivariate correla-
tion analyses with calculation of the coefficient of deter-
mination (R2) were performed. For the bivariate
correlation analyses, changes in PGIC or CGIC were calcu-
lated by coding each category from 1 to 7, with ‘‘no
change’’ treated as the baseline value. Multivariable,
continuous regression analyses were performed to eval-
uate predictive factors for percent changes in VAS and
BPI, with regression coefficient (standard error [SE]) for
the rate of change of a conditional mean of the depen-
dent variable (response variable), and with the coeffi-
cient P value for the significance of the independent
variable (predictor). Multivariable, logistic regression an-
alyses were performed to evaluate predictive factors for
being ‘‘much’’ or ‘‘very much’’ improved on the CGIC or
PGIC, with the odds ratio (OR) for the change in the log
odds of the dependent variable per unit change in the in-
dependent variable, and the P value for the significance
of the predictor. Each regression analysis was performed
twice: 1) with patient demographics (age, sex, and race)
as independent variables, and 2) with patient demo-
graphics plus the VAS and BPI scores at baseline (to test
the role of baseline disease characteristics in influencing
treatment outcomes) and at week 2 (to test the role of
early response in influencing treatment outcomes) as in-
dependent variables. These independent variables were
common for phase 3 and 4 trials and were chosen based
on our knowledge of various variables that can poten-
tially influence treatment outcomes; these included risk
factors for developing PHN, herpes zoster, and other
pain syndromes,6,21,29,38,40,44,45 as well as known factors
differentially associated with the experience of
pain.8,26,34 A positive regression coefficient or OR
indicated that scores on the 2 items changed in the
same direction, and a negative coefficient or OR
indicated that scores on the 2 items changed in
opposite directions. P values were calculated using a
paired, 2-tailed t-test, and statistical significance was
set at P # .05. Correlation and regression analyses were
performed on the efficacy population and, to validate
the results, on the completer population. To test how
well different items measured the same idea and
whether the analysis delivered reliable scores, internal
consistency reliability with calculation of coefficient of
consistency (Cronbach’s alpha) was performed for corre-
lation analyses.Results
Baseline Characteristics
In the phase 3 studies, 721 patients were randomized
to receive G-GR or placebo, and 359 patients received
Randomized
n=721
81-0045 (n=270)
81-0062 (n=451)
Enrolled
 n=201
Received G-GR 
1800 mg once daily
n=359
81-0045 (n=138)
81-0062 (n=221)
Received placebo
n=364
81-0045 (n=133)
81-0062 (n=231)
             Integrated analysis
Efficacy population  n=546
Safety population                  n=556
Completed study                   n=435
Received G-GR 
1800 mg once daily
n=197
Open-label, single arm, multicenter,
Phase 4 study
81-0067
Randomized, double-blind, placebo-controlled, 
multicenter, Phase 3 studies
81-0045
81-0062
Excluded
Figure 1. Patient disposition.
Kantor et al The Journal of Pain 1303$1 dose of G-GR 1800 mg (Fig 1). Patients who received
placebo were not included in the current analyses. In
the phase 4 study, 201 patients were enrolled, and 197
received at least 1 dose of G-GR 1800 mg. For the current
integrated analyses, 546 patients were dosed with G-GR
and were included in the efficacy population, and 435
(79.7%) patients completed the study and were included
in the completer population (Fig 1).
The mean (SD) age of all patients was 66.7 (12.9) years,
and 64.4% of patients were $65 years of age (Table 1).
The majority of patients were female (60.3%) and white
(86.2%). Mean baseline pain intensity on the 100-mm
VAS was 62.2 (Table 2). The highest mean BPI interfer-Table 1. Patient Demographics
G-GR 1800 MG/DAY (N = 556)
Age, y
Mean (SD) 66.7 (12.9)
Median 69.0
(Min, max) (18.0, 92.0)
Age category, n (%)
<55 y 89 (16.0)
55‒64 y 109 (19.6)
65‒74 y 195 (35.1)
$75 y 163 (29.3)
Sex, n (%)
Female 335 (60.3)
Male 221 (39.7)
Race, n (%)
White 479 (86.2)
Hispanic or Latino 38 (6.8)
African American 29 (5.2)
Asian 6 (1.1)
Other 4 (.7)ence scores at baseline, measured on the 0‒10 NRS,
were for worst pain (7.0), average pain (5.7), and current
pain (5.4), as well as sleep interference (5.1) and enjoy-
ment of life (5.0) (Table 2). The lowest BPI mean scores
at baselinewere forwalking ability (2.9) and for relation-
ship (3.3). The BPI average interference score at baseline
was 4.2.Efficacy Measurements at the End of
Treatment
For the measurement of pain intensity using VAS, the
mean reduction from baseline to the end of G-GR treat-
ment was24 (P < .0001) (Table 3). For the measurement
of pain qualities using the BPI scale, the mean change
from baseline in the worst pain (2.4), average pain
(1.9), current pain (2.1), and least pain (1.5) scores
in the last 24 hours were statistically significant
(P < .0001) (Fig 2A). The mean reduction from baseline
to the end of treatment in all 7 individual types of BPI
interference as well as in the average interference score
was also statistically significant (P < .0001) (Fig 2B).
According to the PGIC, the largest group of patients
(45.2%) felt ‘‘much’’ or ‘‘very much’’ improved at the
end of the G-GR treatment; 21.6% of patients reported
feeling ‘‘minimally’’ improved, and 24.5% of patients re-
ported ‘‘no change’’ (Fig 3). The proportion of patients
improved on the CGICwas similar, with 47.2%of patients
feeling ‘‘much’’ or ‘‘very much’’ improved at the end of
G-GR treatment (Fig 3).Correlation
For patients in the efficacy population treated with
G-GR, there were wide-ranging, significant (indicated
by P# .05 for the difference of R2 values from 0), positive
Table 2. Baseline Disease Characteristics
G-GR 1800 MG/DAY (N = 546)
VAS
Mean (SD) 62.2 (18.8)
95% CI 60.6, 63.8
Min‒max 2‒100
BPI worst pain
Mean (SD) 7.0 (1.8)
95% CI 6.9, 7.2
Min‒max 0‒10
BPI least pain
Mean (SD) 4.0 (2.3)
95% CI 3.8, 4.2
Min‒max 0‒10
BPI average pain
Mean (SD) 5.7 (1.8)
95% CI 5.6, 5.9
Min‒max 0‒10
BPI current pain
Mean (SD) 5.4 (2.36)
95% CI 5.2, 5.6
Min‒max 0‒10
BPI general activity
Mean (SD) 4.5 (2.8)
95% CI 4.3, 4.8
Min‒max 0‒10
BPI mood
Mean (SD) 4.7 (2.9)
95% CI 4.5, 5.0
Min‒max 0‒10
BPI walking ability
Mean (SD) 2.9 (3.1)
95% CI 2.6, 3.2
Min‒max 0‒10
BPI normal work
Mean (SD) 4.1 (3.0)
95% CI 3.9, 4.4
Min‒max 0‒10
BPI relationship
Mean (SD) 3.3 (2.9)
95% CI 3.0, 3.5
Min‒max 0‒10
BPI sleep interference
Mean (SD) 5.1 (2.9)
95% CI 4.9, 5.4
Min‒max 0‒10
BPI enjoyment of life
Mean (SD) 5.0 (3.0)
95% CI 4.7, 5.2
Min‒max 0‒10
BPI average interference score
Mean (SD) 4.2 (2.4)
95% CI 4.0, 4.4
Min‒max 0‒10
Abbreviation: CI, confidence interval.
Table 3. Pain Intensity Measured on the VAS at
the End of the Study
G-GR 1800 MG/DAY (N = 546)
End of study
Mean (SD) 37.5 (25.6)
95% CI 35.3, 39.6
Median 34.0
Min‒max 0‒98.0
Change from baseline
Mean (SD) 24.6 (26.2)
95% CI 26.8, 22.4
Median 23.0
Min‒max 93.0‒58.0
P value* <.0001
Abbreviation: CI, confidence interval.
*P value for the difference from baseline is from the Wilcoxon signed rank test.
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Figure 2. Change from baseline in BPI scores. (A) Mean (SEM)
change from baseline in BPI pain scores. (B)Mean (SEM) change
frombaseline in BPI interference scores. *P < .0001 for the differ-
ence from baseline.
1304 The Journal of Pain Treatment of Postherpetic Neuralgia(indicated by all R2 larger than 0) correlations among
percent reductions from baseline to the end of treat-
ment in the efficacy variables (VAS, BPI, CGIC, and
PGIC) (Fig 4A). Generally, correlations among percent
changes in pain scores on the VAS and BPI pain (worst,
least, average, and current pain) were stronger (indi-
cated by R2 values) than those between changes in theVAS/BPI pain and BPI interference (general activity,
mood, walking ability, normal work, relationship, sleep,
enjoyment of life, average) scores. Similarly, correlations
among percent changes in the BPI interference scores
were stronger than those between changes in the BPI
interference and VAS/BPI pain scores. The correlation be-
tween improvements on the PGIC andpercent changes in
other efficacy variables was significant and of moderate
strength, whereas the correlation between CGIC and
other efficacy variables was weak and partially signifi-
cant (Fig 4A).
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Figure 3. Proportion of patients improved on the PGIC and
CGIC.
Kantor et al The Journal of Pain 1305To test whether these correlations were of clinical
significance, the analysis was performed for 3 patient
groups: 1) VAS responders versus nonresponders (those
with $30% reductions in the VAS score versus <30%
reductions), 2) BPI average interference responders
versus nonresponders (those with $30% reductions
in the BPI average interference score versus <30% re-
ductions), and 3) PGIC responders versus nonre-
sponders (patients ‘‘much’’ or ‘‘very much’’ improved
versus patients in all other PGIC categories). Generally,
for VAS responders (Fig 4B) or BPI average interference
responders (Fig 4C), the correlation among percent
changes in various efficacy variables was stronger
(indicated by larger R2 values) and more correlations
were significant compared with nonresponders. In
contrast, there was little difference between PGIC
responders and PGIC nonresponders for percent
changes in various efficacy variables (Fig 4D). The
correlation between improvements on the PGIC and
percent reductions in other efficacy variables was the
weakest for PGIC responders (compare Figs 4B and 4C
with 4D), whereas the correlation between PGIC/CGIC
and other efficacy variables was the strongest for BPI
average interference responders (Fig 4C).
Internal consistency values demonstrated strong in-
ternal consistency: standardized Cronbach’s alpha
was .9473 for analyses among all patients in the effi-
cacy population; it was .9363 for analyses among VAS
responders and .8927 for analyses among VAS nonre-
sponders; it was .9039 for analyses among BPI average
interference responders and .8672 for analyses among
nonresponders; it was .9179 for analyses among PGIC
responders and .9066 for analyses among nonre-
sponders.
To validate the results obtained for the efficacy popu-
lation (ITT populations from individual studies), correla-
tion analyses in the completer population (patients
treated with G-GR who completed individual studies)
were performed. The strength, significance, and profile
of correlations among efficacy variables for the
completer population were similar to those for the effi-
cacy population (Supplementary Fig 1).Predictive Factors
To identify predictive factors for percent changes in
the VAS and BPI scores, as well as for being ‘‘much’’ or
‘‘verymuch’’ improved on the CGIC or PGIC,multivariable
regression analyses with patient demographics (sex, age,
and race) as independent variables were performed. Sex
and age, but not race, were significant predictors for
percent changes in pain measures on the VAS and BPI
(but for changes in BPI interference scores), and for be-
ing improved on the CGIC or PGIC (Table 4). Males were
more likely to report changes on the VAS and the BPI
average pain scores than were females. Older patients
($75 years) were more likely to report changes in the
BPI least pain score than younger patients (<75 years). Fe-
males and older patients were more likely to report
feeling ‘‘much’’ or ‘‘very much’’ improved on the CGIC
or PGIC.
To determine the magnitude of patient demographics
in predicting responses to treatment, we also included
VAS and BPI scores at baseline (baseline disease charac-
teristics) and at week 2 (early response to treatment) as
factors in the regression model. When adjusted for VAS
and BPI scores, patient demographics were not signifi-
cant predictors of percent changes in the VAS and BPI
scores at the end of G-GR treatment (Table 5). VAS or
BPI scores at baseline were negative predictors and
scores at week 2 were positive predictors of percent
changes from baseline to the end of the study in corre-
sponding VAS or BPI variables (Table 5). Besides the base-
line and week 2 VAS scores, the only other predictor of
percent changes in VAS was the BPI average pain score
at baseline. Among all BPI interferences scores, the
only significant predictor for percent changes in the BPI
worst, average, and current pain was the BPI sleep inter-
ference score at week 2. For predictors of changes in
various interference scores, the BPI worst pain score at
baseline was the predictor of percent changes in the
BPI general activity, mood, sleep interference, and enjoy-
ment of life scores. BPI current pain at baseline or at
week 2 was also a common predictor of percent changes
in BPI general activity, mood, enjoyment of life, and
additionally of normal work. Neither of the most com-
mon predictors of changes in various BPI interference
scores significantly predicted percent changes in the
BPI average interference score; instead, the BPI sleep
interference score at baseline was of highest significance
(Table 5).
For predictors of overall improvement, the VAS scores
at baseline and at week 2 were common significant pre-
dictors of ‘‘much’’ or ‘‘very much’’ improvement on the
CGIC or PGIC (Table 5). For being ‘‘much’’ or ‘‘very
much’’ improved on the CGIC, the only other predictive
factor was sex; females were more likely to report im-
provements on the CGIC than males. Other than the
VAS scores, there were 4 more significant predictors of
being ‘‘much’’ or ‘‘very much’’ improved on the PGIC,
and these included BPI current pain at week 2, BPI
normal work and relationship at baseline, and age
(with older patients more likely to report improvement
than younger patients).
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Figure 4. Correlations among percent changes in efficacy measures. The coefficient of determination (R2) was calculated for (A) all
patients in the efficacy population; (B) VAS responders (patients with $30% reduction in VAS) versus VAS nonresponders (patients
with <30% reduction in VAS); (C) BPI average interference responders (patients with $30% reduction in BPI average interference)
versus BPI average interference nonresponders (patients with <30% reduction in BPI average interference); and (D) PGIC responders
(patients feeling ‘‘very much’’ or ‘‘much’’ improved) versus PGIC nonresponders (patients not feeling ‘‘very much’’ or ‘‘much’’
improved). Green indicates the strongest, yellow the intermediate, and red theweakest correlation. *P#.05 for the difference from0.
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analyzed to validate the results in the efficacy popula-
tion, and the results were similar to those presented
above (Supplementary Tables 1 and 2). The most promi-
nent difference was that BPI sleep interference scores
at baseline or at week 2were evenmore common predic-
tors of percent changes in pain qualities; sleep interfer-
ence scores were among predictors for changes in all
BPI pain scores as well as for changes in the VAS.Discussion
Neuropathic pain in general, and PHN in particular, is
associated with poor patient-reported quality of
life,4,20,31 but few studies have examined the impact of
pain relief on patient function or how key patient-
reported outcomes influence each other,15,41,42 and
even fewer have comprehensively analyzed
relationships among efficacy outcomes, patientdemographics, and disease characteristics. This study of
patients with PHN treated with once-daily G-GR provides
in-depth insight into how key patient and disease char-
acteristics may influence the effectiveness of treatment,
and describes complex interactions among reductions
in pain intensity, interference of pain with various as-
pects of patient function, and overall improvement.
The evidence presented may support better understand-
ing of the results of clinical trials, thus leading to more
successful transition to real-world clinical practice.
This study demonstrated wide-ranging positive corre-
lations among changes in self-reported pain intensity,
changes in self-reported daily functioning, and in the
impression of overall improvement. We also found that
correlations among changes in measures of pain inten-
sity on the VAS and BPI scales were generally stronger
than correlations between changes in pain intensity
and pain interference on the BPI inference scale. Simi-
larly, correlations among changes in various measures
Table 4. Patient Demographics as Predictors of Changes in Efficacy Measures at the End of G-GR
Treatment
DEPENDENT VARIABLE PREDICTIVE FACTOR COEFFICIENT (SE) P VALUE
Percent change in VAS Sex (female vs male) 9.86 (4.35) .0239
Percent change in BPI least pain Age ($75 years vs <75 years) 13.40 (6.33) .0346
Percent change in BPI average pain Sex (female vs male) 7.50 (3.75) .0459
DEPENDENT VARIABLE PREDICTIVE FACTOR OR (95% CI) P VALUE
‘‘Much’’ or ‘‘very much’’ improved on CGIC Sex (female vs male) 1.78 (1.25, 2.53) .0015
Age ($75 y vs <75 y) .57 (.39, .84) .0047
‘‘Much’’ or ‘‘Very Much’’ improved on PGIC Sex (female vs male) 1.61 (1.13, 2.29) .0088
Age ($75 y vs <75 y) .60 (.41, .89) .0100
Abbreviation: CI, confidence interval.
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changes in pain interference and pain intensity. These re-
sults are consistent with previous studies showing that
improvement in pain generally relates to improvement
in patient function31,36; however, at least to some
degree, patients may differentiate between self-rated
pain intensity and self-rated pain interference. Also,
weaker intercorrelations between pain intensity and its
interference compared with intracorrelations within
pain intensity and within pain interference may be due
to the fact that some patients can report clinically impor-
tant changes in function without experiencing signifi-
cant reductions in pain intensity.15 In summary, such
wide-ranging positive correlations suggest complex net-
worked systems characterized by positive feedback
loops, where treatment outcomes are in a reciprocal rela-
tionship. An example of such a reciprocal correlation is
that between pain and sleep, where pain disturbs sleep,
and poor sleep enhances pain.23,35,39
The strength and significance of these wide-ranging
correlations among changes in efficacy end points
were dependent on the clinical significance of reduc-
tions in pain intensity and pain interference because
there were differences in the correlation profiles be-
tween patients with $30% versus <30% reduction in
the VAS or BPI average interference (responders vs non-
responders). In contrast, patients divided into 2 groups
based on their PGIC responses (‘‘much’’ or ‘‘very much’’
improved vs not improved) showed similar correlations
among efficacy end points, thus showing no depen-
dence on responses measured on the PGIC. These results
suggest a potentially unique role of assessments of the
overall improvement on the PGIC, showing associations
among treatment outcomes for patients reporting both
clinically significant and not significant improvements
on the PGIC. The relationship between PGIC and other
efficacy measures should be further investigated, at
the level of single variables, to characterize the impact
of assessments on the PGIC in more detail.
Correlation does not generally imply causation, and
we found that despite wide-ranging correlations
among VAS, BPI, CGIC, and PGIC scores, the influence
of these variables on each other was somewhat selec-
tive. Changes in each individual measure of pain inter-
ference assessed on the BPI had distinct predictivefactors, with only a few measures being a common pre-
dictor of change in another measure of pain interfer-
ence. These included the BPI sleep interference scores
at baseline (baseline disease characteristic) and at
week 2 (early response to treatment) as common predic-
tors of changes inmost BPI pain scores and the strongest
predictor of changes in the average of the 7 BPI interfer-
ence scores. In contrast, the overall impression of
improvement at the end of G-GR treatment reported
either by patients (PGIC) or by clinicians (CGIC) ap-
peared to be influenced by patients’ experiencing
pain relief rather than by patients experiencing reduc-
tions in the interference of pain with their functioning;
pain intensity scores on the VAS were predictors of
highest significance for being ‘‘much’’ or ‘‘very much’’
improved on the PGIC or CGIC. In summary, the results
of both predictor and correlation analyses identified
potentially distinctive roles of certain efficacy end
points, which may play an important role in the success-
ful outcome of PHN treatment. Pain relief was not the
only element contributing to successful PHN treatment,
and assessments of pain interference with sleep on the
BPI, and overall improvement on the PGIC in particular,
seemed co-strategic factors. Also, as many trials on
neuropathic pain, including PHN, have recently failed
or showed only moderate treatment effects, it can be
argued that, in addition to standard primary end points
of measures of pain intensity, other co-primary end
points should be considered, possibly assessments of
sleep quality and overall improvement.27,32 This could
not only improve detection of true positive efficacy
responses in trials of PHN and other neuropathic pain
syndromes but also guide successful transition to real-
world clinical practice.
The results of analyses thatwere performedon the inte-
grated efficacy population (ITT populations from individ-
ual studies) were validated and confirmed by the
analyses on the completer population (patients who
completed each individual study). The strength and
pattern of correlation among efficacy outcomes as well
as the profile of predictors of changes in efficacy end
pointswere similar in the completer population compared
with those obtained for the efficacy population. Notice-
ably, the role of BPI sleep interference scores at baseline
or at week 2 in predicting changes in pain intensity on
Table 5. Patient Demographics and Efficacy End Points as Predictors of Changes in Efficacy
Measures at the End of G-GR Treatment
DEPENDENT VARIABLE PREDICTIVE FACTOR COEFFICIENT (SE) P VALUE
Percent change in VAS VAS at baseline 1.25 (.17) <.0001
VAS at wk 2 .64 (.15) <.0001
BPI average pain at baseline 5.38 (2.08) .0099
Percent change in BPI worst pain BPI worst pain at baseline 7.58 (1.48) <.0001
BPI worst pain at wk 2 3.46 (1.32) .0088
BPI average pain at wk 2 4.36 (1.71) .0113
BPI sleep interference at wk 2 2.25 (.89) .0117
VAS at wk 2 .24 (.12) .0460
Percent change in BPI least pain BPI least pain at baseline 13.22 (2.14) <.0001
BPI least pain at wk 2 7.05 (2.24) .0017
BPI average pain at wk 2 7.012 (2.88) .0153
BPI relationship at baseline 3.26 (1.61) .0432
Percent change in BPI average pain BPI average pain at baseline 7.77 (1.75) <.0001
BPI sleep interference at wk 2 2.58 (.93) .0057
BPI average pain at wk 2 4.70 (1.79) .0089
VAS at wk 2 .28 (.12) .0244
Percent change in BPI current pain BPI current pain at baseline 12.33 (2.12) <.0001
BPI current pain at wk 2 6.15 (1.98) .0020
BPI sleep interference at wk 2 3.22 (1.54) .0370
Percent change in BPI general activity BPI general activity at baseline 10.66 (2.21) <.0001
BPI average pain at wk 2 10.04 (3.15) .0015
BPI current pain at wk 2 5.30 (2.00) .0084
BPI least pain at baseline 5.51 (2.19) .0123
BPI relationship at wk 2 4.73 (2.02) .0196
BPI least pain at wk 2 5.04 (2.44) .0399
BPI general activity at wk 2 3.86 (1.98) .0517
BPI worst pain at baseline 5.27 (2.74) .0549
Percent change in BPI mood BPI mood at baseline 11.37 (2.26) <.0001
Sex (female vs male) 16.54 (6.09) .0069
BPI worst pain at baseline 6.97 (2.83) .0141
BPI current pain at wk 2 4.94 (2.11) .0198
BPI relationship at wk 2 4.39 (2.12) .0387
BPI walking ability at baseline 3.77 (1.87) .0444
Percent change in BPI walking ability BPI walking ability at baseline 9.71 (2.86) .0008
Sex (female vs male) 21.72 (9.14) .0182
BPI relationship at wk 2 7.13 (3.20) .0266
BPI walking ability at wk 2 5.63 (2.88) .0515
Percent change in BPI normal work BPI normal work at baseline 13.99 (2.97) <.0001
BPI current pain at baseline 7.48 (2.89) .0100
BPI current pain at wk 2 5.73 (2.77) .0391
Percent change in BPI relationship BPI relationship baseline 19.50 (2.87) <.0001
BPI relationship at wk 2 10.26 (3.22) .0016
BPI walking ability at wk 2 7.19 (2.77) .0097
BPI walking ability at baseline 5.81 (2.56) .0237
BPI least pain at baseline 6.53 (3.16) .0394
BPI general activity at baseline 6.55 (3.33) .0498
Percent change in BPI sleep interference BPI sleep interference at baseline 8.03 (1.77) <.0001
BPI average pain at baseline 8.14 (3.15) .0102
BPI worst pain at baseline 6.68 (2.79) .0170
BPI least pain at wk 2 6.05 (2.57) .0190
BPI average pain at wk 2 7.37 (3.21) .0220
BPI sleep interference at wk 2 3.74 (1.69) .0278
Percent change in BPI enjoyment of life BPI enjoyment of life at baseline 14.02 (2.27) <.0001
BPI enjoyment of life at wk 2 7.00 (2.25) .0020
BPI current pain at baseline 6.89 (2.45) .0052
BPI worst pain at baseline 7.14 (3.24) .0283
BPI average pain at wk 2 8.16 (3.79) .0319
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Table 5. Continued
DEPENDENT VARIABLE PREDICTIVE FACTOR COEFFICIENT (SE) P VALUE
Percent change in BPI average
interference score
BPI sleep interference at baseline 8.32 (3.38) .0140
BPI walking ability at wk 2 8.64 (4.24) .0418
BPI general activity at baseline 8.90 (4.54) .0505
DEPENDENT VARIABLE PREDICTIVE FACTOR OR (95% CI) P VALUE
‘‘Much’’ or ‘‘very much’’ improved on CGIC VAS at wk 2 .97 (.95, .99) .0002
VAS at baseline 1.03 (1.01, 1.05) .0046
Sex (female vs male) 1.58 (1.03, 2.40) .0346
‘‘Much’’ or ‘‘very much’’ improved on PGIC VAS at wk 2 .97 (.96, .99) .0007
VAS at baseline 1.03 (1.01, 1.05) .0045
BPI current pain at wk 2 .82 (.71, .95) .0102
BPI normal work at baseline 1.19 (1.02, 1.39) .0279
BPI relationship at baseline 1.17 (1.01, 1.34) .0353
Age ($75 y vs <75 y) .61 (.38, .97) .0364
Abbreviation: CI, confidence interval.
Kantor et al The Journal of Pain 1309the VAS and pain qualities on the BPI was even more
prominent for the completer population. The analyses
performed on both the efficacy and completer
populations described an important role of pain intensity
in influencing the overall impression of improvement in
patients with PHN, and of the sleep interference score in
influencing changes in both VAS/BPI pain and the BPI
average of interference scores. These results highlight a
key relationship between pain intensity and sleep
interference, and their important role in influencing
patient functioning. This observation is consistent with
the well-described reciprocal relationship between pain
and sleep,23,35,39 and provides further evidence on the
role of pain-sleep interaction on other treatment
outcomes. Further analyses of the relationship between
pain and sleep, and their impact onoverall improvements,
can provide clinically relevant evidence for more compre-
hensive understanding of successful treatment of PHN,
and possibly other neuropathic pain syndromes.
Because of known sex differences in pain perception,
with females generally reporting higher average pain
scores than males,36 and because of age-related modifi-
cations in pain perception,24 sex and age were expected
to be important factors influencing changes in pain in-
tensity and in other measures of treatment outcomes.
However, in this study, these 2 factors did not appear
to play an important role in influencing changes in
patient-rated efficacy measures for both the efficacy
and completer populations, especially when analyses
were adjusted for disease characteristics and early re-
sponses to treatment (efficacy measures at baseline and
at week 2). These results imply that pain intensity and
to what degree it interferes with daily activities play
the key role in influencing treatment outcomes, inde-
pendent of patients’ age or sex. This observation is
consistent with the previous analysis in patients with
PHN treated with G-GR in the phase 3 clinical program
that showed that treatment outcomes and tolerability
were independent of age.12 Thus, for future analyses of
complex relationships, it may be important to consider
patient demographics together with other characteris-tics (eg, disease characteristics and early responses to
treatment) for a more accurate picture of the role of
each variable.
Possible limitations of the analysis presented here
include the fact that changes in pain intensity and pain
interference may simply be influenced by high baseline
scores in respective variables. However, baseline values
were negative (ie, scores on the 2 items change in oppo-
site directions) predictors of percent changes in corre-
sponding efficacy variables for pain intensity or pain
interference. This indicates that high baseline values
did not simply result in big percent changes in outcome
measures at the end of G-GR treatment. Rather, patients’
ability to detect changewas influenced by the severity of
their baseline disease characteristics. Another factor that
could potentially limit or complicate understanding of
relationships as analyzed in this study is the sample
size. Because the sample size affects the regression and
correlation analyses, the number of patients in each
group should be well distributed, with no groups con-
taining a small number of patients. In the current study,
the number of white versus nonwhite patients was not
well distributed (86% vs 14%), which might have
contributed to the lack of significance of this demo-
graphic variable. Therefore, although informative,
multivariable analyses should be carefully designed and
interpreted to avoid drawing incorrect conclusions.
Furthermore, as various scales were used to measure
various treatment outcomes (ie, VAS, BPI pain and inter-
ference, PGIC, and CGIC), we observed a certain level of
scale specificity; for example, changes from baseline in
BPI interference scores were mostly influenced by scores
in other BPI interference scores, and the correlation be-
tween the patient-rated PGIC and other patient-rated ef-
ficacy variables was stronger and of higher significance
than the correlation between the clinician-rated CGIC
and other patient-rated efficacy variables. These suggest
that different scales for measurements of treatment out-
comes and different sources of reporting might have
affected the results of the current analysis to some de-
gree, and these factors should be considered in such
1310 The Journal of Pain Treatment of Postherpetic Neuralgiacomprehensive evaluations of relationships among
treatment outcomes.
This was a unique and comprehensive analysis that
provided an essential insight into how key efficacy mea-
sures and patient and disease characteristics influence
patient-reported treatment outcomes. It revealed wide-
ranging correlations among different efficacy outcomes
in patients with PHN treatedwith once-daily G-GR. These
complex correlations are most likely characterized by
positive feedback loops in which pain interferes with pa-
tient functioning, and poor functioning enhances pain.
Despite the wide-ranging correlations, the influence of
efficacy variables on each other was selective and re-
vealed a potentially important role of 3 factors: pain in-
tensity, pain interference with sleep, and overall
improvement at the end of G-GR treatment. Together,
these results support a well-established reciprocal pain-
sleep correlation, and demonstrate an important role
of this interaction in influencing other treatment out-
comes. Contrary to expectations, patient demographics
did not play an important role, especially when other ef-
ficacy variables were included in the assessment, sug-
gesting that perception of pain and its interference
with daily activities was key for patients self-rating their
treatment, independent of patients’ age or sex.In conclusion, factors characterized in this secondary
analysis of phase 3 and 4 studies may contribute to bet-
ter design and interpretation of clinical trials, withmea-
sures of sleep quality and overall improvements as
potential co-primary end points, along with pain inten-
sity, for improved detection of efficacy responses. Also,
more comprehensive understanding of what factors
lead to effective treatment outcomes will help guide
successful management of PHN in real-world clinical
practice. As PHN treatment remains difficult and often
inadequate, such comprehensive analyses of interac-
tions among efficacy, demographic, and disease charac-
teristic variables from other clinical trials in PHN are
needed for better understanding of the role of each fac-
tor, as well as for better comprehension of the limita-
tions of such analyses, which will translate into
accurate interpretation of the results, their successful
transition to clinical practice, and thus better patient
satisfaction with treatment.Supplementary data
Supplementary data related to this article can be
found at http://dx.doi.org/10.1016/j.jpain.2015.08.011.References
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